Money moves in silence. Download 2025 State of Venture Report: a data-driven analysis of active funds, unicorn, and family offices
About usSign in

Frazier Life Sciences

WebsiteLinkedIncbCrunchbase
Status
Active
Global HQ
California, United States
Countries of investment
  • United States
  • Canada
  • Europe
Investment stages
  • Seed
  • Series A
  • Series B
Industries
  • Biotech
About
Frazier Life Sciences (part of Frazier Healthcare Partners) is a biotech VC based in Seattle, leading highly curated investments in therapeutics with significant track record in creating and scaling firms.
Min check size
$100K
Max check size
$1M
Fund size
NPS

Investment Thesis

Invests in novel therapeutic companies—from company creation through Series A/B—focused on transformative life sciences.
Lead investor
Co Invest
Number of exits
Preferred contact method

Manager's Experience

With a robust background in investment management, the fund manager has successfully executed over 50 deals, primarily targeting growth-stage companies in the technology and healthcare sectors. Leveraging a data-driven approach, they have built a diverse portfolio across North America and Europe, emphasizing operator-first strategies. Noteworthy exits include several high-profile acquisitions that have significantly boosted returns for investors. Their thematic focus on innovation and market disruption positions them uniquely in the competitive landscape.

Frazier Life Sciences Contacts Information

Primary contact

Secondary contact

Team

Albert Cha

M.D.

Ph.D. – Managing Partner; James N. Topper

M.D.

Ph.D. – Managing Partner; Patrick Heron – Managing Partner; Daniel Estes

Ph.D. – General Partner; James W. Brush

M.D. – General Partner & Portfolio Manager; Anna H. Chen

Ph.D. – Partner; Aditya Kohli

Ph.D. – Partner; Joe Cabral – Principal; Kevin Li

M.D. – Principal; Lin Mu

M.D.

MBA – Vice President; Angel Martin

Ph.D. – Senior Associate; Jason Wang – Senior Associate; Kiah Williams

M.D. – Senior Associate; Xinghuo Li

Ph.D. – Associate; Chris Wittenborn – Trader; Gordon Empey – Chief Operating Officer

General Counsel and Partner; Ali Jackson – Vice President and Counsel

Public Funds; Ailsa Dalgliesh

Ph.D. – Head of Investor Relations; Kei Nakazono – IT Director; Shu Yeung – Director

Human Resources; Adam Simpson – Venture Partner; James Li

M.D. – Venture Partner; Maria Fardis

Ph.D. – Venture Partner; Mitch Gold

M.D. – Venture Partner; Robert Hershberg

M.D.

Ph.D. – Venture Partner; Stanford Peng

M.D.

Ph.D. – Venture Partner; Tao Fu

M.D.

Ph.D. – Venture Partner; Azmi Nabulsi

M.D.

M.P.H. – Entrepreneur‑in‑Residence; Brian Farmer – Entrepreneur‑in‑Residence; Chris Peetz – Entrepreneur‑in‑Residence; Gordon McMurray

Ph.D. – Entrepreneur‑in‑Residence; Ian W. Mills

B.M.

B.CH.

D.M. – Entrepreneur‑in‑Residence; Scott Byrd – Entrepreneur‑in‑Residence; Lauren Mifflin

Ph.D. – Principal of Company Creation; Christopher Aakre

Ph.D. – Principal of Company Creation; Zaneta Odrowaz

Ph.D. – Vice President of Company Creation; Alan Frazier – Chairman Emeritus; Angie You

Ph.D. – Senior Advisor; Bhaskar Chaudhuri

Ph.D. – Senior Advisor; Scott Wasserman

M.D. – Venture Partner; James Li

M.D. – Venture Partner

Portfolio

Arcutis Biotherapeutics

Phathom Pharmaceuticals

Lengo Therapeutics

Amunix Pharmaceuticals

Acerta Pharma

Krystal Biotech

Chinook Therapeutics

Sierra Oncology

Fund number
Vintage Year
Net Internal Rate of Return
Investment Multiple
Capital Allocation
Management Fee
Carried Interest
AUM
Follow-on Investments
Graduation Rate
Write-Off Ratio
Last profile update timestamp